- Home
- EICA vs OSRHW Comparison
EICA vs OSRHW Comparison
Compare EICA & OSRHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | EICA | OSRHW |
|---|---|---|
| Founded | N/A | N/A |
| Country | | United States |
| Employees | N/A | 21 |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | EICA | OSRHW |
|---|---|---|
| Price | $24.59 | $0.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | N/A |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | N/A |
| 52 Week High | N/A | N/A |
Technical Indicators
Market Signals| Indicator | EICA | OSRHW |
|---|---|---|
| Relative Strength Index (RSI) | 42.64 | N/A |
| Support Level | $24.55 | N/A |
| Resistance Level | $24.66 | N/A |
| Average True Range (ATR) | 0.06 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 10.00 | 0.00 |
Price Performance
Historical ComparisonAbout EICA Eagle Point Income Company Inc. 5.00% Series A Term Preferred Stock due 2026
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About OSRHW OSR Holdings Inc. Warrant
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.